NOS1 and melanoma: The results, along with accumulating evidence [10,12,17,26,27], provide insight into the pro-tumorigenic activity of IFN-γ and underscore the potential of targeting nNOS and COX-2 as promising pharmacotherapeutic approaches for melanoma by inhibiting IFN-γ-stimulated PD-L1 expression (Figure 9).